Drug intelligence / Profile preview

Flublok

Development stage: Approved
Lead developer: Sanofi
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Flublok is a recombinant, egg-free influenza vaccine developed by Protein Sciences Corporation (now a subsidiary of Sanofi). It is produced using the baculovirus expression vector system (BEVS) in an insect cell line (expresSF+), which allows for the production of hemagglutinin (HA) proteins without the need for live influenza virus or chicken eggs. The vaccine contains a higher concentration of HA antigen (45 mcg per strain) compared to standard-dose vaccines. It is indicated for active immunization against seasonal influenza in adults aged 18 years and older and is available in both trivalent and quadrivalent formulations.

Brand names: FlublokFlublok Quadrivalent
Other names: Recombinant Influenza VaccineRIVRIV3RIV-3RIV 3RIV4RIV-4RIV 4

Targets

HA (Hemagglutinin)

Beyond the preview

Go deeper on Flublok.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Flublok.

Explore the full profile